A new study reports the results of Phase 1, a first-in-human study investigating the safety, tolerability, & pharmacokinetics of CVN424 (a GPR6 inverse agonist being developed by cerevance for Parkinson's) in healthy volunteers.
jpet.aspetjournals.org/cont...
results
"A total of 64 subjects were enrolled, 48 received CVN424 (30 in the SAD cohorts and 18 in the
MAD cohorts), and 16 received placebo (10 in the SAD cohorts and 6 in the MAD cohorts). One
MAD subject who received 75 mg dose of CVN424 discontinued early because of an adverse
event of dysphagia; all other subjects completed the study as per protocol."
Claimed improvement in symptoms following dental treatment.
